Krook, Melanie A.
Reeser, Julie W.
Ernst, Gabrielle
Barker, Hannah
Wilberding, Max
Li, Gary http://orcid.org/0000-0003-4090-7179
Chen, Hui-Zi
Roychowdhury, Sameek http://orcid.org/0000-0002-8297-3038
Article History
Received: 8 April 2020
Revised: 6 August 2020
Accepted: 21 October 2020
First Online: 3 December 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: All data are included in the review article.
: S.R. participated in Advisory Boards for Incyte Corporation (2017), AbbVie Inc. (2017) and QED Therapeutics (2018, 2019). S.R. received honoraria from IDT Integrated DNA Technologies (2017), Illumina (2018). S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019). S.R. received travel reimbursement from Incyte Corporation (2019). G.L. is an employee and shareholder of QED Therapeutics, an affiliate of BridgeBio Pharma. The other authors declare that there are no competing interests.
: S.R. has received grant support from the American Cancer Society Mentored Research Scholar Grant, NCI UH2CA202971 (OSU-SpARKFuse) and Pelotonia. M.A.K. has received grant support from a T32 Oncology Training Grant (5T32CA009338) and Award Number Grant TL1TR002735 from the National Centre for Advancing Translational Sciences. M.W. has received grant support from a Pelotonia undergraduate fellowship. H.-Z.C. has received grant support from an NCI K08 grant (K08CA241309).